To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...

—These findings suggest that conventional imaging significantly underestimates the extent of disease in high-risk, biochemically recurrent prostate cancer, potentially impacting treatment decisions ...

Patients who reported current multivitamin use had a lower risk of recurrence than patients who had never taken multivitamins. Patients with prostate cancer may have a lower risk of recurrence if they ...

Many patients with high-risk biochemically recurrent prostate cancer based on PSA doubling time are unidentified in clinical practice. Clinicians unaware of patients’ PSA doubling time (PSADT) at ...

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive global trial has found that a combination of two medications, enzalutamide ...

While prostate cancer recurrence is a major cause of death in patients receiving localized treatment, there are other significant causes of mortality. While prostate cancer progression or recurrence ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a ...

For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before the cancer comes back. Researchers at UCLA have found that a blend of a ...

Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic body radiotherapy (SBRT) went more than twice as long without their disease ...

Gozellix performance for imaging of biochemically recurrent prostate cancer appears to be affected by serum PSA levels and site of disease; for imaging of metastatic pelvic lymph nodes prior to ...

Adding the drug enzalutamide to standard hormone therapy reduced deaths by more than 40% in men with recurrent prostate cancer. The international study, published in The New England Journal of ...